Gensight Biologics (France) Price Prediction

SIGHT Stock  EUR 0.32  0.01  3.23%   
At this time, the value of RSI of Gensight Biologics' share price is approaching 42. This usually implies that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Gensight Biologics, making its price go up or down.

Oversold Vs Overbought

42

 
Oversold
 
Overbought
The successful prediction of Gensight Biologics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Gensight Biologics SA, which may create opportunities for some arbitrage if properly timed.
Using Gensight Biologics hype-based prediction, you can estimate the value of Gensight Biologics SA from the perspective of Gensight Biologics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Gensight Biologics to buy its stock at a price that has no basis in reality. In that case, they are not buying Gensight because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Gensight Biologics after-hype prediction price

    
  EUR 0.32  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Gensight Biologics Basic Forecasting Models to cross-verify your projections.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Gensight Biologics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.010.284.78
Details
Naive
Forecast
LowNextHigh
0.010.334.83
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.270.340.41
Details

Gensight Biologics After-Hype Price Prediction Density Analysis

As far as predicting the price of Gensight Biologics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Gensight Biologics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Gensight Biologics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Gensight Biologics Estimiated After-Hype Price Volatility

In the context of predicting Gensight Biologics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Gensight Biologics' historical news coverage. Gensight Biologics' after-hype downside and upside margins for the prediction period are 0.02 and 4.82, respectively. We have considered Gensight Biologics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
0.32
0.32
After-hype Price
4.82
Upside
Gensight Biologics is out of control at this time. Analysis and calculation of next after-hype price of Gensight Biologics is based on 3 months time horizon.

Gensight Biologics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Gensight Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gensight Biologics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Gensight Biologics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.28 
4.50
 0.00  
 0.00  
0 Events / Month
0 Events / Month
Within a week
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.32
0.32
0.00 
0.00  
Notes

Gensight Biologics Hype Timeline

Gensight Biologics is at this time traded for 0.32on Euronext Paris of France. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Gensight is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is projected to be very small, whereas the daily expected return is at this time at -0.28%. %. The volatility of related hype on Gensight Biologics is about 0.0%, with the expected price after the next announcement by competition of 0.32. About 13.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.68. Gensight Biologics had not issued any dividends in recent years. Assuming the 90 days trading horizon the next projected press release will be within a week.
Check out Gensight Biologics Basic Forecasting Models to cross-verify your projections.

Gensight Biologics Related Hype Analysis

Having access to credible news sources related to Gensight Biologics' direct competition is more important than ever and may enhance your ability to predict Gensight Biologics' future price movements. Getting to know how Gensight Biologics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Gensight Biologics may potentially react to the hype associated with one of its peers.

Gensight Biologics Additional Predictive Modules

Most predictive techniques to examine Gensight price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Gensight using various technical indicators. When you analyze Gensight charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Gensight Biologics Predictive Indicators

The successful prediction of Gensight Biologics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Gensight Biologics SA, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Gensight Biologics based on analysis of Gensight Biologics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Gensight Biologics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Gensight Biologics's related companies.

Story Coverage note for Gensight Biologics

The number of cover stories for Gensight Biologics depends on current market conditions and Gensight Biologics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Gensight Biologics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Gensight Biologics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Other Macroaxis Stories

Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios

Gensight Biologics Short Properties

Gensight Biologics' future price predictability will typically decrease when Gensight Biologics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Gensight Biologics SA often depends not only on the future outlook of the potential Gensight Biologics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Gensight Biologics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding45.2 M
Cash And Short Term Investments44.3 M

Additional Tools for Gensight Stock Analysis

When running Gensight Biologics' price analysis, check to measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.